SWOG clinical trial number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Open
Phase
III
Accrual
0%
Abbreviated Title
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or…
Status Notes
This study is open to accrual effective February 16, 2021.
Activated
02/16/2021
Participants
ALLIANCE, ECOG-ACRIN, NRG, SWOG
Research committees
Genitourinary Cancer
Treatment
Gemcitabine hydrochloride
Eribulin mesylate
Other Clinical Trials
SWOG Clinical Trial Number
S1937
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Research Committee(s)
Genitourinary Cancer
Activated
02/16/2021
Accrual
0%
Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
10/01/2019
Open
SWOG Clinical Trial Number
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
27%
Open
Phase
III